Leveraged Finance Fights Melanoma (LFFM) is the most influential gathering of executives from the leveraged finance, private equity, and investment sectors, united in the fight against melanoma—the deadliest form of skin cancer. Leveraged finance visionary pioneers such as Michael Milken, Leon Black, Carl Icahn, Henry Kravis, and Howard Marks have headlined this flagship event.
Since its inception in 2011, co-founders Jeffrey Rowbottom and Brendan Dillon—both personally touched by melanoma—have galvanized this annual event to raise over $27 million, directly fueling groundbreaking research and skin cancer prevention efforts.
MRA’s research advancements, supported by LFFM, have transformed the melanoma landscape, bringing 15 of the 17 new treatments to market since LFFM’s launch. The impact extends beyond melanoma, as therapies pioneered here are now being explored across more than 30 types of cancer, setting new standards in oncology.
For more information on sponsorships and event information, please contact Janine Rauscher at jrauscher@curemelanoma.org.
Thank you to the 2024 NYC Leveraged Finance Fights Melanoma community for raising record breaking $4 million from over 100 leveraged finance firms, 100% benefitting melanoma research.
Clare Bailhé (MidCap Financial), Brendan Dillon (Veritas Capital), Kerry Dolan (Brinley Partners), Lee Grinberg (Elliott Management), Jason Kanner (Kirkland & Ellis), Matt Manin (Apollo), Eliza McDougall (White & Case), Erwin Mock (Thoma Bravo), George Mueller (KKR), Geoff Oltmans (Silver Lake), Kevin Pluff (HPS Investment Partners), Jeff Rowbottom (General Atlantic Credit), Ian Schuman (Latham & Watkins), Cade Thompson (KKR), Brian Steinhardt (Simpson Thacher & Bartlett), Trevor Watt (Hellman & Friedman), & Eric Wedel (Paul, Weiss, Rifkind, Wharton & Garrison)
